251. Bioconjugation of luminescent silicon quantum dots for selective uptake by cancer cells
- Author
-
Wing Cheung Law, Hong Ding, Ken-Tye Yong, Indrajit Roy, Chen An Tien, Mark T. Swihart, Folarin Erogbogbo, Ching Wen Chang, and Paras N. Prasad
- Subjects
Silicon ,Luminescence ,Surface Properties ,Biomedical Engineering ,Pharmaceutical Science ,Bioengineering ,Nanotechnology ,Folic Acid ,Coated Materials, Biocompatible ,Cell Line, Tumor ,Materials Testing ,Quantum Dots ,Molecule ,Humans ,Particle Size ,Pharmacology ,chemistry.chemical_classification ,Bioconjugation ,Molecular Structure ,Chemistry ,Biomolecule ,Lysine ,Organic Chemistry ,technology, industry, and agriculture ,Transferrin ,Stereoisomerism ,equipment and supplies ,Imaging agent ,Molecular Imaging ,Pancreatic Neoplasms ,Quantum dot ,Covalent bond ,Molecular imaging ,Biotechnology - Abstract
Conventional quantum dots have great potential in cancer-related imaging and diagnostic applications; however, these applications are limited by concerns about the inherent toxicity of their core materials (e.g., cadmium, lead). Virtually all imaging applications require conjugation of the imaging agent to a biologically active molecule to achieve selective uptake or binding. Here, we report a study of biocompatible silicon quantum dots covalently attached to biomolecules including lysine, folate, antimesothelin, and transferrin. The particles possess desirable physical properties, surface chemistry, and optical properties. Folate- and antimesothelin-conjugated silicon quantum dots show selective uptake into Panc-1 cells. This study contributes to the preclinical evaluation of silicon quantum dots and further demonstrates their potential as an imaging agent for cancer applications.
- Published
- 2011